{"url_path":"/sec/sgmt/8-k/2026-04-27/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-048971-index.html","accession_number":"0001104659-26-048971","cik":"0001400118","ticker":"SGMT","issuer_name":"Sagimet Biosciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-048971-index.html","primary_entity_key":"0001400118","primary_entity_name":"Sagimet Biosciences Inc."},"word_count":321,"has_tables":true,"body_markdown":"false\n0001400118\n\n0001400118\n\n2026-04-27\n2026-04-27\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n \n\n \n\n**FORM 8-K**\n\n \n\n \n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d)**\n\n**of the Securities Exchange Act of 1934**\n\n \n\n**Date of Report (Date of earliest event reported):\nApril 27, 2026**\n\n \n\n \n\n \n\n**SAGIMET BIOSCIENCES INC.**\n\n**(Exact name of registrant as specified in its\ncharter)**\n\n \n\n \n\n \n\n**Delaware**\n**001-41742**\n**20-5991472**\n\n**(State or other jurisdiction**\n\n**of incorporation)**\n**(Commission** **File Number)**\n**(I.R.S. Employer**\n\n**Identification No.)**\n\n \n\n**Sagimet Biosciences Inc.**\n\n**155 Bovet Road, Suite 303,**\n\n**San Mateo, California 94402**\n\n**(Address of principal executive offices, including\nzip code)**\n\n \n\n**(650) 561-8600**\n\n**(Registrant’s telephone number, including\narea code)**\n\n \n\n**Not Applicable**\n\n**(Former Name or Former Address, if Changed Since\nLast Report)**\n\n \n\n \n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨\nWritten communications pursuant\nto Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨\nSoliciting material pursuant\nto Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨\nPre-commencement communications\npursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨\nPre-commencement communications\npursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\nTrade\n\nSymbol(s)\nName of each exchange on which registered\n\nSeries A Common Stock, $0.0001 par value per share\nSGMT\nThe Nasdaq Global Market\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities\nExchange Act of 1934 (§ 240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company x\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}